Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA) filed this Form 8-K on September 29, 2025, reporting the completion of its acquisition of SKNY Pharmaceuticals, Inc. (SKNY). The transaction was executed via a Merger Agreement, resulting in MIRA acquiring 100% of SKNY in exchange for restricted common stock. The filing also addresses the company's status regarding Nasdaq listing compliance.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: Restricted shares of MIRA common stock issued to SKNY shareholders based on an exchange ratio derived from independent third-party valuations.
- Liquidity Injection: SKNY contributed $5 million in marketable securities to MIRA at closing.
- Equity Issuance: Shares were issued under Section 4(a)(2) of the Securities Act of 1933 and Rule 506.
- Financial Statements: This 8-K does not provide specific revenue, profit, cash flow, or debt figures for the reporting period.
Material Changes
- Pipeline Expansion: The acquisition transforms MIRA into a multi-program biopharmaceutical developer with three key candidates:
- Ketamir-2: Next-generation ketamine analog in Phase 1 for neuropathic pain; preclinical data suggests activity in depression and PTSD.
- MIRA-55: Oral THC analog for inflammatory pain, cognitive decline, and anxiety, designed to avoid addictive risks.
- SKNY-1: Oral therapeutic for obesity and smoking cessation; preclinical results indicate up to 30% weight loss without muscle loss.
- Listing Compliance: MIRA previously received a Nasdaq deficiency notice on April 8, 2025, for failing to meet the $2.5 million stockholders' equity requirement. Following an extension granted until October 6, 2025, the company states it has regained compliance through at-the-market stock sales and the SKNY merger closing.
Outlook, Risks, and Management Commentary
Management views the SKNY acquisition as a "transformational step" that strengthens the financial position and broadens the pipeline to address unmet medical needs. The company believes it has satisfied Nasdaq Rule 5550(b)(1) requirements as of the report date. However, the filing notes that Nasdaq will continue to monitor compliance, and failure to evidence compliance in the next periodic report could result in delisting.
Investor Verification Checklist
- Verify the exact number of MIRA shares issued to SKNY shareholders and the resulting dilution impact.
- Confirm the current stockholders' equity balance to ensure sustained compliance with Nasdaq listing rules beyond the October 6, 2025 deadline.
- Review the independent third-party valuations used to determine the exchange ratio for the merger.
- Monitor upcoming periodic reports for confirmation of Nasdaq's formal acceptance of the company's compliance status.